Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2020 Jul 10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Cardioangiologica 2020 Jul 10

DOI: 10.23736/S0026-4725.20.05219-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cardiac contractility modulation in left ventricular systolic dysfunction: one-year experience in a pilot study and design of a prospective registry

Mario MATTA , Chiara DEVECCHI, Federica DE VECCHI, Lorella BARBONAGLIA, Miriam GRAVELLONE, Eraldo OCCHETTA, Francesco RAMETTA

Cardiology Division, Sant’Andrea Hospital, Vercelli, Italy


PDF


BACKGROUND: Cardiac contractility modulation (CCM) is a treatment option for patients suffering symptomatic chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF) who are not eligible for cardiac resynchronization. Data on mid-term follow-up are limited to small observational studies. The aim of this study is to assess the impact of CCM on quality of life, symptoms, exercise tolerance and left ventricular function in patients with CHF and moderate-to- severe left ventricular systolic dysfunction.
METHOS: Patients suffering CHF with LVEF <45% and NYHA class > II despite optimal medical therapy, underwent CCM implantation. Enrolled patients underwent baseline and 3-, 6- and 12- months evaluation with ECG, echocardiogram, clinical assessment, 6-minute walking test and Minnesota Living With Heart Failure Questionnaire (MLWHFQ).
RESULTS: Ten patients underwent CCM implantation. All patients were actively treated with the optimal pharmacological therapy as tolerated, and had at least one hospitalization for worsening heart failure during the previous year. After a mean follow-up of 15 months, 9 patients were alive, while one patient died for worsening heart failure precipitated by pneumonia. Among the remaining 9 patients, LVEF improved non-significantly from 29.4±8% to 32.2±10% (p=0.092), 6-minute walking test distance improved from 179±73 m to 304±99 m (p<0.001), NYHA class reduced from 3.0±0.4 to 1.6±0.5 (p=0.003) and MLWHFQ score improved from 59.6±49 to 34.2±32 (p=0.037). Only 2 patients have been hospitalized during the 12 months. Overall, a net clinical benefit was detected in 6 out of 9 patients.
CONCLUSIONS: CCM could be effective in improving quality of life, symptoms and exercise tolerance, and reduces hospitalizations in patients with symptomatic CHF on top of optimal medical and electrical therapy. A prospective registry has been designed to identify the subsets of patients gaining more benefit, and to assess the long-term effect of CCM on those clinical endpoints.


KEY WORDS: Cardiac contractility modulation; Heart failure; Exercise tolerance; Device implantation; Quality of life

inizio pagina